Hyaluronic Acid Viscosupplementation | Market Insights | Global | 2023
The COVID-19 pandemic has had a negative impact on the HA viscosupplementation market due to cancelation and postponement of elective treatments. Following that, treatment volumes have been increasing as restrictions were eased and substantial percentages of the populations are vaccinated. Beyond the impact of pandemic, favorable demographics, improved physician training, increased patient awareness, and overall marketing efforts by the companies, as well as continued product innovation, will support the modestly growing HA viscosupplementation market. Furthermore, premium-priced 1-injection products will continue to become more popular over the forecast period, whereas 3- and 5-injection products will continue to be preferred in some countries due to differences in product access, cost, and reimbursement.
This Medtech 360 Report provides comprehensive data and analysis on the state of the market for HA viscosupplementation in the US, Europe, Asia Pacific, and Brazil from 2019 through 2031.
